<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33340024</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Improving clinical trial outcomes in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>104</StartPage><EndPage>118</EndPage><MedlinePgn>104-118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-020-00434-z</ELocationID><Abstract><AbstractText>Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s - a lack of effective therapies. In part, the development of new treatments has been hampered by an imperfect understanding of the biological processes that trigger ALS and promote disease progression. Advances in our understanding of these biological processes, including the causative genetic mutations, and of the influence of environmental factors have deepened our appreciation of disease pathophysiology. The consequent identification of pathogenic targets means that the introduction of effective therapies is becoming a realistic prospect. Progress in precision medicine, including genetically targeted therapies, will undoubtedly change the natural history of ALS. The evolution of clinical trial designs combined with improved methods for patient stratification will facilitate the translation of novel therapies into the clinic. In addition, the refinement of emerging biomarkers of therapeutic benefits is critical to the streamlining of care for individuals. In this Review, we synthesize these developments in ALS and discuss the further developments and refinements needed to accelerate the introduction of effective therapeutic approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia. matthew.kiernan@sydney.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. matthew.kiernan@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sydney Medical School Westmead, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Sheffield Biomedical Research Centre, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Neurology Unit, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-5067-5602</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix, Creighton University, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-6504-8107</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talman</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9866-9068</Identifier><AffiliationInfo><Affiliation>Neurosciences Department, Barwon Health District, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dharmadasa</LastName><ForeName>Thanuja</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6544-1091</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wicks</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2293-9284</Identifier><AffiliationInfo><Affiliation>Wicks Digital Health, Lichfield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reilly</LastName><ForeName>Claire</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5602-814X</Identifier><AffiliationInfo><Affiliation>The Motor Neurone Disease Association of New Zealand, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091369">Immunomodulating Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091369" MajorTopicYN="N">Immunomodulating Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33340024</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pii">10.1038/s41582-020-00434-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Disease International. World Alzheimer report 2019: attitudes to dementia (ADI, 2019).</Citation></Reference><Reference><Citation>Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N. Engl. J. Med. 2013;368:1326&#x2013;1334. doi: 10.1056/NEJMsa1204629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsa1204629</ArticleId><ArticleId IdType="pmc">PMC3959992</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global action plan on the public health response to dementia 2017&#x2013;2025 (WHO, 2017).</Citation></Reference><Reference><Citation>Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010&#x2013;2050) estimated using the 2010 census. Neurology. 2013;80:1778. doi: 10.1212/WNL.0b013e31828726f5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828726f5</ArticleId><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, et al. The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. Expert Rev. Neurother. 2020;20:281&#x2013;293. doi: 10.1080/14737175.2020.1727740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1727740</ArticleId><ArticleId IdType="pubmed">32031423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:639. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Pastula D, Welsh E, Pulley D, Cudkowicz ME. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph. Lateral Scler. 2008;9:257&#x2013;265. doi: 10.1080/17482960802195913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802195913</ArticleId><ArticleId IdType="pubmed">18608092</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 2020;113:1975&#x2013;1978. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Matamala JM, Howells J, Vucic S, Kiernan MC. Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: a regional study across the motor cortices. Clin. Neurophysiol. 2020;131:958&#x2013;966. doi: 10.1016/j.clinph.2019.11.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.11.057</ArticleId><ArticleId IdType="pubmed">31959568</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37:433&#x2013;442. doi: 10.1016/j.tins.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.05.006</ArticleId><ArticleId IdType="pubmed">24927875</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, et al. Occasional essay: upper motor neuron syndrome in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2020;91:227&#x2013;234. doi: 10.1136/jnnp-2019-321938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321938</ArticleId><ArticleId IdType="pubmed">32054724</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, et al. Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clin. Neurophysiol. 2016;127:2643&#x2013;2660. doi: 10.1016/j.clinph.2016.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2016.04.025</ArticleId><ArticleId IdType="pubmed">27291884</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon NG, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann. Neurol. 2014;76:643&#x2013;657. doi: 10.1002/ana.24273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24273</ArticleId><ArticleId IdType="pmc">PMC4305209</ArticleId><ArticleId IdType="pubmed">25223628</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Kiernan MC, Swash M. Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. J. Neurol. Neurosurg. Psychiatry. 2017;88:773&#x2013;779. doi: 10.1136/jnnp-2017-315574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315574</ArticleId><ArticleId IdType="pubmed">28490504</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, et al. Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry. 2017;88:1042. doi: 10.1136/jnnp-2017-315995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair IP, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J. Neurol. Neurosurg. Psychiatry. 2010;81:639&#x2013;645. doi: 10.1136/jnnp.2009.194399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.194399</ArticleId><ArticleId IdType="pubmed">19965854</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J. Neurol. Neurosurg. Psychiatry. 2013;84:931&#x2013;935. doi: 10.1136/jnnp-2012-304529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304529</ArticleId><ArticleId IdType="pubmed">23463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case&#x2013;control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2013;74:699&#x2013;708. doi: 10.1002/ana.23969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23969</ArticleId><ArticleId IdType="pubmed">23836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MHB, et al. Family history of neurodegenerative and vascular diseases in ALS. Neurology. 2011;77:1363-1369. doi: 10.1212/WNL.0b013e318231530b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318231530b</ArticleId><ArticleId IdType="pubmed">21940614</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, et al. Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology. 2018;91:e1498&#x2013;e1507. doi: 10.1212/WNL.0000000000006344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006344</ArticleId><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien M, et al. Clustering of neuropsychiatric disease in first-degree and second-degree relatives of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2017;74:1425&#x2013;1430. doi: 10.1001/jamaneurol.2017.2699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2699</ArticleId><ArticleId IdType="pmc">PMC5822189</ArticleId><ArticleId IdType="pubmed">29049464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C-LG, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589&#x2013;602. doi: 10.1016/S0896-6273(00)80997-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80997-6</ArticleId><ArticleId IdType="pubmed">9539131</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotti D, Rolfs A, Danbolt NC, Brown RH, Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 1999;2:427&#x2013;433. doi: 10.1038/8091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/8091</ArticleId><ArticleId IdType="pubmed">10321246</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2018;89:367&#x2013;373. doi: 10.1136/jnnp-2017-316605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, et al. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J. Neurol. Neurosurg. Psychiatry. 2018;89:374&#x2013;381. doi: 10.1136/jnnp-2017-316365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316365</ArticleId><ArticleId IdType="pmc">PMC5869447</ArticleId><ArticleId IdType="pubmed">29101254</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94&#x2013;109. doi: 10.1016/S1474-4422(08)70293-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70293-X</ArticleId><ArticleId IdType="pubmed">19081518</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RP, et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 2018;89:156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015;14:478&#x2013;484. doi: 10.1016/S1474-4422(15)00014-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00014-9</ArticleId><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2016;17:580&#x2013;588. doi: 10.1080/21678421.2016.1188961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1188961</ArticleId><ArticleId IdType="pubmed">27249331</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013;136:1361&#x2013;1370. doi: 10.1093/brain/awt085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt085</ArticleId><ArticleId IdType="pubmed">23616585</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, Agosta F, Grosskreutz J, Filippi M, Turner MR. Neuroimaging endpoints in amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14:11&#x2013;23. doi: 10.1007/s13311-016-0484-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0484-9</ArticleId><ArticleId IdType="pmc">PMC5233627</ArticleId><ArticleId IdType="pubmed">27752938</ArticleId></ArticleIdList></Reference><Reference><Citation>McMackin R, et al. Measuring network disruption in neurodegenerative diseases: new approaches using signal analysis. J. Neurol. Neurosurg. Psychiatry. 2019;90:1011&#x2013;1020. doi: 10.1136/jnnp-2018-319581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319581</ArticleId><ArticleId IdType="pmc">PMC6820156</ArticleId><ArticleId IdType="pubmed">30760643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, et al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann. Clin. Transl. Neurol. 2019;6:1081&#x2013;1089. doi: 10.1002/acn3.795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.795</ArticleId><ArticleId IdType="pmc">PMC6562031</ArticleId><ArticleId IdType="pubmed">31211172</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Poly (GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann. Neurol. 2017;81:718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, Marchetto MC, Bardy C, Gage FH. Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nat. Rev. Neurosci. 2016;17:424. doi: 10.1038/nrn.2016.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.46</ArticleId><ArticleId IdType="pmc">PMC6276815</ArticleId><ArticleId IdType="pubmed">27194476</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A, Del Valle Palomo Ruiz M, Perez DI, Gil C. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs. 2017;26:403&#x2013;414. doi: 10.1080/13543784.2017.1302426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1302426</ArticleId><ArticleId IdType="pubmed">28277881</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev. 2006;12:9&#x2013;20. doi: 10.1111/j.1527-3458.2006.00009.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3458.2006.00009.x</ArticleId><ArticleId IdType="pmc">PMC6741743</ArticleId><ArticleId IdType="pubmed">16834755</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J. Neurol. 2020;267:3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. July 2017 ENCALS statement on edaravone. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:471&#x2013;474. doi: 10.1080/21678421.2017.1369125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, &#xd6;zdinler PH, Kiernan MC, Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat. Rev. Neurol. 2016;12:651. doi: 10.1038/nrneurol.2016.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.140</ArticleId><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudzinski LA, et al. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel. J. Investig. Med. 2016;64:1087&#x2013;1101. doi: 10.1136/jim-2016-000151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2016-000151</ArticleId><ArticleId IdType="pubmed">27252470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1&#x2013;11. doi: 10.1016/j.celrep.2014.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis. A randomized clinical trial. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e465. doi: 10.1212/NXI.0000000000000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadiri M, et al. Dimethyl fumarate&#x2013;induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol. Neuroimmunol. Neuroinflamm. 2017;4:e340. doi: 10.1212/NXI.0000000000000340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000340</ArticleId><ArticleId IdType="pmc">PMC5365096</ArticleId><ArticleId IdType="pubmed">28377940</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, et al. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant) Medicine. 2020;99:e18904. doi: 10.1097/MD.0000000000018904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018904</ArticleId><ArticleId IdType="pmc">PMC7015658</ArticleId><ArticleId IdType="pubmed">32028398</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol. Lett. 2007;114:1&#x2013;8. doi: 10.1016/j.imlet.2007.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2007.08.005</ArticleId><ArticleId IdType="pmc">PMC2094047</ArticleId><ArticleId IdType="pubmed">17936914</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03039673 (2019).</Citation></Reference><Reference><Citation>US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT02059759 (2016).</Citation></Reference><Reference><Citation>Camu W, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2020;59:102844. doi: 10.1016/j.ebiom.2020.102844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102844</ArticleId><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="pubmed">32651161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrage LC, et al. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol. Genet. Metab. 2014;113:131&#x2013;135. doi: 10.1016/j.ymgme.2014.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2014.06.005</ArticleId><ArticleId IdType="pmc">PMC4177960</ArticleId><ArticleId IdType="pubmed">25042691</ArticleId></ArticleIdList></Reference><Reference><Citation>Obici L, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19:34&#x2013;36. doi: 10.3109/13506129.2012.678508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13506129.2012.678508</ArticleId><ArticleId IdType="pubmed">22551192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler. 2009;10:99&#x2013;106. doi: 10.1080/17482960802320487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802320487</ArticleId><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Trial of sodium phenylbutyrate&#x2013;taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in ALS. Muscle Nerve. 2020 doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>TUDCA ALS. New clinical trial for ALS/MND. TUDCAhttps://www.tudca.eu/ (2020).</Citation></Reference><Reference><Citation>Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol. 2004;251:1080&#x2013;1084. doi: 10.1007/s00415-004-0481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0481-5</ArticleId><ArticleId IdType="pubmed">15372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, et al. Rasagiline for amyotrophic lateral sclerosis: a randomized, controlled trial. Muscle Nerve. 2019;59:201&#x2013;207. doi: 10.1002/mus.26335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26335</ArticleId><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17:681&#x2013;688. doi: 10.1016/S1474-4422(18)30176-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30176-5</ArticleId><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310&#x2013;322. doi: 10.1016/S1474-4422(13)70036-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70036-X</ArticleId><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry. 2016;87:1234. doi: 10.1136/jnnp-2014-308350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308350</ArticleId><ArticleId IdType="pmc">PMC5099318</ArticleId><ArticleId IdType="pubmed">27172939</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, et al. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:917. doi: 10.1136/jnnp-2017-315573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315573</ArticleId><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J. Neurol. Neurosurg. Psychiatry. 2014;85:1232. doi: 10.1136/jnnp-2013-307135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307135</ArticleId><ArticleId IdType="pubmed">24648037</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson RD, Garton FC, Kiernan MC, Turner MR, Eisen A. Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2019;90:570&#x2013;575. doi: 10.1136/jnnp-2017-317245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317245</ArticleId><ArticleId IdType="pmc">PMC6581076</ArticleId><ArticleId IdType="pubmed">29666205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Ziemann U, Eisen A. Amyotrophic lateral sclerosis: origins traced to impaired balance between neural excitation and inhibition in the neonatal period. Muscle Nerve. 2019;60:232&#x2013;235. doi: 10.1002/mus.26617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26617</ArticleId><ArticleId IdType="pubmed">31233613</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, et al. ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology. 2020;94:e1657. doi: 10.1212/WNL.0000000000009015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009015</ArticleId><ArticleId IdType="pmc">PMC7251515</ArticleId><ArticleId IdType="pubmed">32071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanka V, Wieland S, Barber J, Cudkowicz M. Arimoclomol: a potential therapy under development for ALS. Expert Opin. Investig. Drugs. 2009;18:1907&#x2013;1918. doi: 10.1517/13543780903357486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543780903357486</ArticleId><ArticleId IdType="pubmed">19938902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve. 2008;38:837&#x2013;844. doi: 10.1002/mus.21059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21059</ArticleId><ArticleId IdType="pubmed">18551622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha Y, et al. Drug repurposing from the perspective of pharmaceutical companies. Br. J. Pharmacol. 2018;175:168&#x2013;180. doi: 10.1111/bph.13798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13798</ArticleId><ArticleId IdType="pmc">PMC5758385</ArticleId><ArticleId IdType="pubmed">28369768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083&#x2013;1091. doi: 10.1016/S1474-4422(14)70222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PD, et al. A high-throughput screen to identify inhibitors of SOD1 transcription. Front. Biosci. 2012;4:2801-2808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083181</ArticleId><ArticleId IdType="pubmed">22652679</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JD, et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J. Biomol. Screen. 2014;19:44&#x2013;56. doi: 10.1177/1087057113501553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057113501553</ArticleId><ArticleId IdType="pmc">PMC3913261</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead RJ, et al. S [+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2013;61:438&#x2013;452. doi: 10.1016/j.freeradbiomed.2013.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.04.018</ArticleId><ArticleId IdType="pmc">PMC3684770</ArticleId><ArticleId IdType="pubmed">23608463</ArticleId></ArticleIdList></Reference><Reference><Citation>Benmohamed R, et al. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2011;12:87&#x2013;96. doi: 10.3109/17482968.2010.522586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.522586</ArticleId><ArticleId IdType="pmc">PMC8131116</ArticleId><ArticleId IdType="pubmed">21073276</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberstadt M, et al. TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole. Sci. Rep. 2018;8:2248. doi: 10.1038/s41598-018-20565-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20565-0</ArticleId><ArticleId IdType="pmc">PMC5797228</ArticleId><ArticleId IdType="pubmed">29396541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitoh H, et al. ALS-linked mutant SOD1 induces ER stress-and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008;22:1451&#x2013;1464. doi: 10.1101/gad.1640108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1640108</ArticleId><ArticleId IdType="pmc">PMC2418582</ArticleId><ArticleId IdType="pubmed">18519638</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen EJ, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurol. 2018;14:214. doi: 10.1038/nrneurol.2018.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2018.4</ArticleId><ArticleId IdType="pubmed">29422644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, et al. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138:3110&#x2013;3122. doi: 10.1093/brain/awv220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv220</ArticleId><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyawasam D, Alexander IE, Kurian M, Farrar MA. Great expectations: virus-mediated gene therapy in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 2020;91:849&#x2013;860. doi: 10.1136/jnnp-2019-322327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322327</ArticleId><ArticleId IdType="pubmed">32503884</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CE, Zain R. Therapeutic oligonucleotides: state of the art. Annu. Rev. Pharmacol. Toxicol. 2019;59:605&#x2013;630. doi: 10.1146/annurev-pharmtox-010818-021050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010818-021050</ArticleId><ArticleId IdType="pubmed">30285540</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoasii L, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science. 2018;362:86&#x2013;91. doi: 10.1126/science.aau1549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau1549</ArticleId><ArticleId IdType="pmc">PMC6205228</ArticleId><ArticleId IdType="pubmed">30166439</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann. Clin. Transl. Neurol. 2018;5:730&#x2013;740. doi: 10.1002/acn3.567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.567</ArticleId><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson KA, Cudkowicz ME, Berry JD. Clinical trial designs in amyotrophic lateral sclerosis: does one design fit all? Neurotherapeutics. 2015;12:376&#x2013;383. doi: 10.1007/s13311-015-0341-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0341-2</ArticleId><ArticleId IdType="pmc">PMC4404442</ArticleId><ArticleId IdType="pubmed">25700798</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M. Clinical trials in the ALS syndrome: it is time for change. J. Neurol. Neurosurg. Psychiatry. 2019;90:1308. doi: 10.1136/jnnp-2018-319248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319248</ArticleId><ArticleId IdType="pubmed">31366603</ArticleId></ArticleIdList></Reference><Reference><Citation>DasMahapatra P, Raja P, Gilbert J, Wicks P. Clinical trials from the patient perspective: survey in an online patient community. BMC Health Serv. Res. 2017;17:166. doi: 10.1186/s12913-017-2090-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-017-2090-x</ArticleId><ArticleId IdType="pmc">PMC5327530</ArticleId><ArticleId IdType="pubmed">28241758</ArticleId></ArticleIdList></Reference><Reference><Citation>Collet M. How much does distance limit the pool of potential clinical trial participants in the United States? F1000Research. 2017 doi: 10.7490/f1000research.1115158.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.7490/f1000research.1115158.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini M, et al. Challenges with novel clinical trial designs: master protocols. Clin. Cancer Res. 2019;25:2049&#x2013;2057. doi: 10.1158/1078-0432.CCR-18-3544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3544</ArticleId><ArticleId IdType="pubmed">30696689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: review and new trial designs. Contemp. Clin. Trials Commun. 2018;12:1&#x2013;8. doi: 10.1016/j.conctc.2018.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conctc.2018.08.009</ArticleId><ArticleId IdType="pmc">PMC6120722</ArticleId><ArticleId IdType="pubmed">30182068</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin. Trials. 2016;13:358&#x2013;366. doi: 10.1177/1740774515626362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774515626362</ArticleId><ArticleId IdType="pubmed">26908536</ArticleId></ArticleIdList></Reference><Reference><Citation>Connick P, et al. Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open. 2018;8:e021944. doi: 10.1136/bmjopen-2018-021944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-021944</ArticleId><ArticleId IdType="pmc">PMC6119433</ArticleId><ArticleId IdType="pubmed">30166303</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern, A. D. &amp; Mehta, S. Adaptive platform trials: the clinical trial of the future? Harvard Business Schoolhttps://www.hbs.edu/faculty/Pages/item.aspx?num=53315 (2017).</Citation></Reference><Reference><Citation>US Food and Drug Administration. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry (FDA, 2018).</Citation></Reference><Reference><Citation>Rosenfeld J. Multi-drug therapy in amyotrophic lateral sclerosis: the case for a multi-drug approach. Muscle Nerve. 2004;30:673&#x2013;675. doi: 10.1002/mus.20186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20186</ArticleId><ArticleId IdType="pubmed">15452840</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SB, et al. Flecainide in amyotrophic lateral sclerosis as a neuroprotective strategy (FANS): a randomized placebo-controlled trial. EBioMedicine. 2015;2:1916&#x2013;1922. doi: 10.1016/j.ebiom.2015.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.022</ArticleId><ArticleId IdType="pmc">PMC4703720</ArticleId><ArticleId IdType="pubmed">26844270</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch. Neurol. 2006;63:557&#x2013;560. doi: 10.1001/archneur.63.4.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.4.557</ArticleId><ArticleId IdType="pubmed">16606769</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DH, II, Miller RG. Improving efficiency of ALS clinical trials using lead-in designs. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2004;5(Suppl. 1):57&#x2013;60. doi: 10.1080/17434470410019997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17434470410019997</ArticleId><ArticleId IdType="pubmed">15512875</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;1194. doi: 10.1016/S1474-4422(16)30199-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J. Neurol. Neurosurg. Psychiatry. 2015;86:45&#x2013;49. doi: 10.1136/jnnp-2013-306865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306865</ArticleId><ArticleId IdType="pubmed">24463480</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry. 2019;90:1165&#x2013;1170. doi: 10.1136/jnnp-2018-320288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320288</ArticleId><ArticleId IdType="pmc">PMC6817985</ArticleId><ArticleId IdType="pubmed">31315908</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;772. doi: 10.1007/s13311-016-0508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry. 2016;87:628&#x2013;632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:595&#x2013;604. doi: 10.1080/21678421.2019.1632899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632899</ArticleId><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719&#x2013;1725. doi: 10.1212/WNL.0000000000000951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramacere I, et al. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2015;86:1180&#x2013;1185. doi: 10.1136/jnnp-2014-310176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-310176</ArticleId><ArticleId IdType="pubmed">25886781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, et al. Comparison of the King&#x2019;s and MiToS staging systems for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:227&#x2013;232. doi: 10.1080/21678421.2016.1265565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1265565</ArticleId><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Iazzolino B, et al. Validation of the revised classification of cognitive and behavioural impairment in ALS. J. Neurol. Neurosurg. Psychiatry. 2019;90:734. doi: 10.1136/jnnp-2018-319696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319696</ArticleId><ArticleId IdType="pubmed">30733331</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91:e1370&#x2013;e1380. doi: 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, et al. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013;81:1350&#x2013;1355. doi: 10.1212/WNL.0b013e3182a823e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a823e0</ArticleId><ArticleId IdType="pmc">PMC3806927</ArticleId><ArticleId IdType="pubmed">24005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J. Neurol. Neurosurg. Psychiatry. 2019;90:451&#x2013;457. doi: 10.1136/jnnp-2018-319294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319294</ArticleId><ArticleId IdType="pmc">PMC6581107</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:61&#x2013;67. doi: 10.1080/21678421.2018.1541095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1541095</ArticleId><ArticleId IdType="pmc">PMC6513689</ArticleId><ArticleId IdType="pubmed">30486680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, Vaughan TE, Massagli MP, Heywood J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat. Biotechnol. 2011;29:411. doi: 10.1038/nbt.1837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1837</ArticleId><ArticleId IdType="pubmed">21516084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:384&#x2013;393. doi: 10.1007/s13311-014-0331-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0331-9</ArticleId><ArticleId IdType="pmc">PMC4404434</ArticleId><ArticleId IdType="pubmed">25582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A phase 2, double-blind, randomized, dose-ranging trial of Reldesemtiv in patients with ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020 doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A, et al. Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial. Amyotroph. Lateral Scler. 2012;13:210&#x2013;216. doi: 10.3109/17482968.2011.633268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.633268</ArticleId><ArticleId IdType="pmc">PMC3310482</ArticleId><ArticleId IdType="pubmed">22292842</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R, et al. Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:285&#x2013;293. doi: 10.1080/21678421.2018.1556698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1556698</ArticleId><ArticleId IdType="pubmed">30663902</ArticleId></ArticleIdList></Reference><Reference><Citation>ALSUntangled Group. ALSUntangled no. 26: lunasin. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:622&#x2013;626. doi: 10.3109/21678421.2014.959297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959297</ArticleId><ArticleId IdType="pubmed">25245186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808&#x2013;812. doi: 10.1212/WNL.0000000000002251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002251</ArticleId><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. Muscle Nerve. 2018;58:42&#x2013;48. doi: 10.1002/mus.26117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26117</ArticleId><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, et al. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86:1474&#x2013;1481. doi: 10.1212/WNL.0000000000002507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002507</ArticleId><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PC, Hsieh YC, Huang CC, Hu CJ. Tamoxifen for amyotrophic lateral sclerosis: a randomized double-blind clinical trial. Medicine. 2020;99:e20423. doi: 10.1097/MD.0000000000020423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000020423</ArticleId><ArticleId IdType="pubmed">32481440</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S, et al. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:15&#x2013;23. doi: 10.1080/21678421.2019.1672750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1672750</ArticleId><ArticleId IdType="pubmed">31608711</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TD, Bowser R, Hank N, Saperstein D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph. Lateral Scler. 2010;11:514&#x2013;519. doi: 10.3109/17482968.2010.513052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.513052</ArticleId><ArticleId IdType="pubmed">20839903</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:456&#x2013;460. doi: 10.3109/17482968.2010.498521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.498521</ArticleId><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi Z, et al. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement. Amyotroph. Lateral Scler. Frontotemporal Degener. 2015;16:345&#x2013;352. doi: 10.3109/21678421.2015.1026826.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026826</ArticleId><ArticleId IdType="pmc">PMC4610861</ArticleId><ArticleId IdType="pubmed">25832828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17:681&#x2013;688. doi: 10.1016/S1474-4422(18)30176-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30176-5</ArticleId><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565&#x2013;e574. doi: 10.1212/WNL.0000000000004960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004960</ArticleId><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>